Lucitanib Clinical Development Overview
Lucitanib, an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Clovis has global rights (excluding China) for lucitanib.
Recent data for a drug that inhibits these same three pathways - when combined with a PD-1 inhibitor - are extremely encouraging and represent a scientific rationale for the development of lucitanib in combination with a PD-1 inhibitor, and a Clovis-sponsored Phase 1b/2 study of lucitanib in combination with nivolumab in advanced gynecologic cancers and other solid tumors is currently enrolling. Based on encouraging data of VEGF and PARP inhibitors in combination, a Phase 1b/2 study of lucitanib in combination with rucaparib in advanced ovarian cancer is also enrolling as an arm of the SEASTAR study. Anticipate initial data from these Clovis-sponsored studies at medical meetings in 2020.
Lucitanib Scientific Presentations
Combination of the Angiogenesis Inhibitor Lucitanib with Immune Checkpoint Blockade Augments Anti-tumor Activity in Syngeneic Models
Presented at 2019 SITC